Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic ModelLauren E. Abrey, Lisa M. DeAngelis, Leah Ben‐Porat et al.|Journal of Clinical Oncology|2006Cited by 620
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelCraig H. Moskowitz, Joachim Yahalom, Stephen D. Nimer et al.|Blood|2001Cited by 427
Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's LymphomaCraig H. Moskowitz, Andrew D. Zelenetz, Joseph R. Bertino et al.|Journal of Clinical Oncology|1999Cited by 303
Rapamycin-Sensitive Pathway Regulates Mitochondrial Membrane Potential, Autophagy, and Survival in Irradiated MCF-7 CellsShoshana Paglin, Joachim Yahalom|Cancer Research|2005Cited by 216
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016Steven M. Horwitz, Pierluigi Porcu, Martha Glenn et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 141